AstraZeneca

AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden

Wednesday, May 20, 2015 03:18 PM

AstraZeneca plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics. The new facility will supply medicines for clinical trial programs of AZ and MedImmune, the company's global biologics R&D arm, from the end of 2018, and will deliver finished products for commercial use once fully operational by 2019.

More... »

Quest Diagnostics

AstraZeneca inks personalized medicine partnerships with Abbott, Montreal Heart Institute

Wednesday, May 13, 2015 12:07 PM

AstraZeneca has formed collaborations with the Montreal Heart Institute (MHI) in Quebec, Canada, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes, and with Abbott to develop companion diagnostic tests to identify patients with severe asthma who are most likely to benefit from the investigational biological therapy tralokinumab.

More... »


Moderna launches venture company Elpidera for rare diseases

Wednesday, May 13, 2015 11:57 AM

Moderna Therapeutics, a Cambridge, Mass.-based developer of messenger RNA (mRNA) Therapeutics, has launched Elpidera, a new Moderna venture focused exclusively on the advancement of mRNA-based medicines for the treatment of rare diseases.

More... »

Surface Oncology appoints Detlev Biniszkiewicz CEO

Monday, May 11, 2015 09:09 AM

Surface Oncology, a Cambridge, Mass.-based provider of next-generation cancer immunotherapies, has appointed Detlev Biniszkiewicz, Ph.D., president and CEO, effective immediately. Biniszkiewicz brings over 15 years of industry leadership and experience building a transformative pipeline of novel cancer therapies, most recently as the head of the oncology strategy at AstraZeneca.

More... »

Flagship Ventures partners with AstraZeneca, Nestlé, Bayer

Wednesday, May 6, 2015 02:48 PM

Flagship Ventures, a venture capital and venture creation firm focused on innovations in healthcare and sustainability, has formed strategic innovation partnerships with AstraZenecaNestlé Health Science and Bayer CropScience. These collaborations will allow Flagship to scale up its unique innovation foundry, VentureLabs, as well as expand its early stage venture funding activities while leveraging the partners' strengths as market leaders.

More... »

AstraZeneca, Celgene collaborate on serious blood cancers

Friday, May 1, 2015 12:51 PM

AstraZeneca and MedImmune, AZ’s global biologics R&D arm, have entered into an exclusive collaboration agreement with Celgene for the development and commercialization of MEDI4736 across a range of blood cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma.

More... »

Safe-Biopharma launches cyber security consulting service for life science, healthcare

Friday, April 24, 2015 01:18 PM

SAFE-BioPharma Association has created SBP Digital Trust Consulting, a resource of internationally recognized identity and access management (IAM) policy and technical experts for life science and healthcare companies seeking to develop improved cyber security strategies.

More... »

Incyte joins Safe-Biopharma Association

Friday, April 17, 2015 12:39 PM

Incyte, a Delaware-based biopharmaceutical company, has joined SAFE-BioPharma Association, a nonprofit industry coalition responsible for the ongoing development and implementation of the SAFE-BioPharma digital identity and signature standard.

More... »

Immunocore, MedImmune collaborate on immuno-oncology combination trials

Friday, April 17, 2015 12:36 PM

Immunocore, a biotechnology company developing novel biological drugs to treat cancer and other diseases headquartered outside Oxford, England, and MedImmune, the global biologics R&D arm of AstraZeneca, have entered into a second collaboration.

More... »

Icon executives release book for re-engineering clinical trials

Wednesday, April 15, 2015 12:50 PM

Global CRO Icon of Dublin, Ireland, has released the book Re-Engineering Clinical Trials, edited and co-authored by Brendan Buckley, Icon’s chief medical officer, and Peter Schüler, ICON’s senior vice president of global medical and safety services.

More... »


CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs